- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01005940
Dental Device for Treatment of Sleep Apnea (OSA-MAD)
Health Outcomes of Treatment of Obstructive Sleep Apnea With Dental Devices
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with obstructive sleep apnea (OSA) will be included in this prospective controlled trial. OSA patients who are unable to tolerate CPAP or refuse CPAP(Continuous positive airway pressure) (and who are deemed appropriate by their attending physician for dental device treatment of OSA will be randomized to a control group (no MAD treatment) or to active MAD therapy.
Epidemiologic studies suggest that OSA is associated with insulin resistance independent of other known risk factors such as obesity. The cyclic intermittent hypoxia in OSA is the primary stimulus that leads to insulin resistance, a primary risk factor for the development of type 2 diabetes. There is an association between the level of hypoxic stress in OSA and insulin resistance.
The overall hypothesis to be tested is that treatment of OSA with MAD will improve insulin sensitivity, increase levels of HMW (High-molecular- weight) adiponectin, and improve psychological adjustment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Apnea-hypopnea index (AHI) of at least 20 events/hr based on overnight polysomnography
- > 18 years of age
- Unable to tolerate or refuse CPAP treatment
Exclusion Criteria:
- Known diabetes mellitus
- Body mass index (BMI) > 45 kg/m2
- Uncontrolled hypertension
- Known congestive heart failure
- Use of illicit drugs
Excessive alcohol consumption, defined as:
- More than 3 glasses of wine a day
- More than 3 beers a day
- More than 60 mL of hard liquor a day
- Room air oxyhemoglobin saturation < 90%
- Use of home oxygen
- Use of corticosteroids
- Unable to give voluntary consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mandibular advancement device
Subject is evaluated when receiving intervention with mandibular advancement device.
|
Mandibular advancement device made to subject specific specifications
|
|
No Intervention: No mandibular advancement device
Subject is evaluated when not receiving treatment with mandibular advancement device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Treatment of OSA with mandibular advancement device results in improvements in insulin sensitivity
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Treatment of OSA with mandibular advancement device increases the levels of high-molecular-weight adiponectin in the circulation
Time Frame: 16 weeks
|
16 weeks
|
|
Treatment of OSA with mandibular advancement device improves psychological adjustment.
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ulysses Magalang, M.D., Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009H0131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea Syndromes
-
Mardin Artuklu UniversityEnrolling by invitationObstructive Sleep Apnea SyndromesTurkey (Türkiye)
-
Mardin Artuklu UniversityNot yet recruitingObstructive Sleep Apnea | Sleep ApneaTurkey (Türkiye)
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI); ResMed FoundationRecruitingObstructive Sleep Apnea | Sleep ApneaUnited States
-
Hospices Civils de LyonNot yet recruitingObstructive Sleep ApneaFrance
-
University Hospital, AntwerpNot yet recruiting
-
Nyxoah Inc.Not yet recruitingObstructive Sleep ApneaUnited States
-
Restera, Inc.RecruitingObstructive Sleep ApneaAustralia
-
China Medical University HospitalRecruiting
-
ProSomnus Sleep TechnologiesActive, not recruiting
Clinical Trials on Mandibular advancement device
-
Tuiuti University of ParanáNot yet recruitingGastroesophageal Reflux DiseaseBrazil
-
Amsterdam UMC, location VUmcAcademic Centre for Dentistry in AmsterdamNot yet recruitingObstructive Sleep Apnea
-
Hawler Medical UniversityNot yet recruitingSleep Apnea, ObstructiveIraq
-
Ain Shams UniversityCompletedObstructive Sleep ApneaEgypt
-
Henry Ford Health SystemWithdrawnPregnancy Related | Obstructive Sleep Apnea of AdultUnited States
-
Singapore General HospitalCompletedObstructive Sleep ApneaSingapore
-
VU University of AmsterdamCompleted
-
University of ValenciaNot yet recruiting
-
University Hospital, AntwerpImelda Hospital, Bonheiden; Vitaz; Heilig Hart Ziekenhuis Lier; AZ Monica Campus... and other collaboratorsCompletedObstructive Sleep Apnea (OSA) | Mandibular Advancement DeviceBelgium